Rigel Pharmaceuticals【RIGL】銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

21.526

買値

21.35

売値

21.48

出来高

18,001

21.13 日の範囲 21.79

7.4843 52 週間の範囲 29.82

時価総額

379.181M

前日終値

21.74

始値

21.57

時刻

21.5267

最終取引時間

00:18:13

財務取引量

US$ 387,125

VWAP

21.5057

平均取引量 (3 か月)

293,015

発行済株式数

17,615,040

配当利回り

PER

-15.07

1 株当たり利益 (EPS)

-1.42

歳入

116.88M

純利益

-25.09M

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For mor... Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit https://www.rigel.com/. 詳細を表示

セクター

Pharmaceutical Preparations

業界

Pharmaceutical Preparations

ウェブサイト

www.rigel.com

本社

Wilmington, Delaware, USA

設立

Rigel Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker RIGL. The last closing price for Rigel Pharmaceuticals was US$21.74. Over the last year, Rigel Pharmaceuticals shares have traded in a share price range of US$ 7.4843 to US$ 29.82.

Rigel Pharmaceuticals currently has 17,615,040 shares in issue. The market capitalisation of Rigel Pharmaceuticals is US$382.95 million. Rigel Pharmaceuticals has a price to earnings ratio (PE ratio) of -15.07.

Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease

Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease PR Newswire SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 First patient enrolled in...

Form 8-K - Current report

Rigel Provides Business Update and 2025 Outlook

Rigel Provides Business Update and 2025 Outlook PR Newswire SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 Preliminary fourth quarter 2024 total revenue of approximately $57.6 million which includes...

Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS

Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS PR Newswire SOUTH SAN FRANCISCO, Calif., Jan. 9, 2025 SOUTH SAN FRANCISCO, Calif., Jan. 9, 2025 /PRNewswire/ -- Rigel...

Rigel to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Rigel to Present at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire SOUTH SAN FRANCISCO, Calif., Jan. 8, 2025 SOUTH SAN FRANCISCO, Calif., Jan. 8, 2025 /PRNewswire/ -- Rigel...

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) PR Newswire SOUTH SAN FRANCISCO, Calif., Jan. 3, 2025 SOUTH SAN FRANCISCO, Calif., Jan. 3, 2025...

Form 8-K - Current report

Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition

Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition PR Newswire SOUTH SAN FRANCISCO, Calif., Dec. 9, 2024 R289 was...

Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS

Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS PR Newswire SOUTH SAN FRANCISCO, Calif., Dec. 2, 2024 SOUTH SAN FRANCISCO, Calif., Dec. 2, 2024 /PRNewswire/...

Form 4 - Statement of changes in beneficial ownership of securities

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	3.526	19.5888888889	18	22.06	17.28	321001	20.62752879	CS
4	5.086	30.9367396594	16.44	22.06	15.5	362680	17.61472428	CS
12	7.406	52.4504249292	14.12	29.82	13.5705	293015	20.69641825	CS
26	11.646	117.874493927	9.88	29.82	8.61	203357	18.32260246	CS
52	8.426	64.320610687	13.1	29.82	7.4843	753687	12.44323519	CS
156	-2.674	-11.0495867769	24.2	35.15	6.4	2137683	13.60098849	CS
260	-5.774	-21.1501831502	27.3	55	6.4	2435562	22.84608691	CS

RIGL - Frequently Asked Questions (FAQ)

What is the current Rigel Pharmaceuticals share price?

The current share price of Rigel Pharmaceuticals is US$ 21.526

How many Rigel Pharmaceuticals shares are in issue?

Rigel Pharmaceuticals has 17,615,040 shares in issue

What is the market cap of Rigel Pharmaceuticals?

The market capitalisation of Rigel Pharmaceuticals is USD 382.95M

What is the 1 year trading range for Rigel Pharmaceuticals share price?

Rigel Pharmaceuticals has traded in the range of US$ 7.4843 to US$ 29.82 during the past year

What is the PE ratio of Rigel Pharmaceuticals?

The price to earnings ratio of Rigel Pharmaceuticals is -15.07

What is the cash to sales ratio of Rigel Pharmaceuticals?

The cash to sales ratio of Rigel Pharmaceuticals is 3.24

What is the reporting currency for Rigel Pharmaceuticals?

Rigel Pharmaceuticals reports financial results in USD

What is the latest annual turnover for Rigel Pharmaceuticals?

The latest annual turnover of Rigel Pharmaceuticals is USD 116.88M

What is the latest annual profit for Rigel Pharmaceuticals?

The latest annual profit of Rigel Pharmaceuticals is USD -25.09M

What is the registered address of Rigel Pharmaceuticals?

The registered address for Rigel Pharmaceuticals is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801

What is the Rigel Pharmaceuticals website address?

The website address for Rigel Pharmaceuticals is www.rigel.com

Which industry sector does Rigel Pharmaceuticals operate in?

Rigel Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
DGNXDiginex Ltd	US$ 18.4515 (146.02%)	5.68M
HEPAHepion Pharmaceuticals Inc	US$ 0.1939 (43.63%)	212.77M
NITON2OFF Inc	US$ 1.13 (40.37%)	59.23M
DWTXDogwood Therapeutics Inc	US$ 3.6995 (32.13%)	784.41k
LITMSnow Lake Resources Ltd	US$ 1.68 (27.27%)	12.73M
ICONIcon Energy Corporation	US$ 0.4659 (-64.44%)	6.35M
JUNSJupiter Neurosciences Inc	US$ 1.5536 (-56.60%)	2.98M
SGLYSingularity Future Technology Ltd	US$ 2.5006 (-32.42%)	527.41k
WHLRLWheeler Real Estate Investment Trust Inc	US$ 99.76 (-31.44%)	12
CDTConduit Pharmaceuticals Inc	US$ 0.0459 (-26.56%)	25.82M
HEPAHepion Pharmaceuticals Inc	US$ 0.1939 (43.63%)	212.77M
TNXPTonix Pharmaceuticals Holding Corporation	US$ 0.3683 (15.45%)	62.1M
NITON2OFF Inc	US$ 1.13 (40.37%)	59.23M
KOPNKopin Corporation	US$ 1.839 (25.10%)	57.46M
RGTIRigetti Computing Inc	US$ 13.665 (-1.76%)	54.29M